Show simple item record

dc.contributor.authorFINN, STEPHENen
dc.contributor.authorO'LEARY, JOHNen
dc.date.accessioned2014-02-27T15:21:14Z
dc.date.available2014-02-27T15:21:14Z
dc.date.issued2014en
dc.date.submitted2014en
dc.identifier.citationO'Brien CP, Taylor SE, O'Leary JJ, Finn SP, Molecular testing in oncology: Problems, pitfalls and progress., Lung cancer (Amsterdam, Netherlands), 2014en
dc.identifier.issn0169-5002en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/68174
dc.descriptionPUBLISHEDen
dc.description.abstractRecent advances in the understanding of the molecular basis of cancer and the development of molecular diagnostics based on this knowledge have done much to progress the fields of oncology and pathology. Technological developments such as Next Generation Sequencing (NGS) and multiplex assays have made feasible the widespread adoption of molecular diagnostics for clinical use. While these developments and advances carry much promise, there are pitfalls to implementing this testing. Choosing appropriate biomarkers is a vital first step for clinical use and being able to understand the complex relationship between predictive and prognostic biomarkers is a crucial component of this. Testing for standard of care biomarkers is not straightforward, one must choose carefully between clinical trial assays, assays that analyse the same biological phenomenon or surrogate biomarkers. Sample heterogeneity and population specific difference is assays may skew results and must be controlled for at the assay design stage. At a technical level, NGS has the potential to revolutionise laboratory practice and approaches to cancer treatment. However, use of this technology requires careful planning and implementation if one is to avoid technical and ethical quagmires. Finally, with FDA regulation of companion diagnostics one may be limited to therapy specific assays.en
dc.language.isoenen
dc.relation.ispartofseriesLung cancer (Amsterdam, Netherlands)en
dc.rightsYen
dc.subjectCanceren
dc.titleMolecular testing in oncology: Problems, pitfalls and progress.en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/finnsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/olearyjjen
dc.identifier.rssinternalid92019en
dc.identifier.doihttp://dx.doi.org/10.1016/j.lungcan.2013.12.010en
dc.rights.ecaccessrightsOpenAccess
dc.identifier.orcid_id0000-0002-8628-5814en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record